Back to Search
Start Over
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
- Source :
-
Experimental hematology [Exp Hematol] 2006 Jun; Vol. 34 (6), pp. 770-5. - Publication Year :
- 2006
-
Abstract
- Objective: We investigated the effect of at least two cycles of bortezomib (1.3 mg/m(2) intravenously, days 1, 4, 8, and 11) after dose-reduced allogeneic stem cell transplantation (SCT) on toxicity, CD3(+) cells, graft-versus-host disease (GvHD), and response in patients with multiple myeloma.<br />Methods: Eighteen patients with multiple myeloma without progressive disease were included. The proteasome inhibitor was given at median of 8 months after allografting to enhance or maintain remission status.<br />Results: Fourteen patients (78%) completed the proposed two cycles. Four patients had to discontinue therapy due to neurotoxicity (n = 3) or gastrointestinal toxicity (n = 1). Severe grade III/IV toxicity was seen for thrombocytopenia (50%), leukopenia (17%), or neuropathy (17%), which was more often seen in patients treated concomitantly with cyclosporine (p = 0.06). The median circulating CD3(+) cells decreased during treatment from 550 muL to 438 muL (p = 0.03), resulting in herpes zoster infection in three patients (17%). In three patients, a mild aggravation of existing acute or chronic GvHD of the skin, and in one patient de novo skin grade I acute GvHD was noted. In patients with measurable disease, complete remission, partial remission, and minor response was seen in 3 (30%), 5 (50%), and 2 (20%) patients, respective.<br />Conclusion: Bortezomib after allogeneic SCT is effective but further studies are needed to balance the efficacy with potential hazards such as infectious complications, aggravation of GvHD, and neurotoxicity.
- Subjects :
- Adult
Antineoplastic Agents adverse effects
Boronic Acids adverse effects
Bortezomib
CD3 Complex blood
Chronic Disease
Cyclosporine administration & dosage
Cyclosporine adverse effects
Disease-Free Survival
Female
Graft vs Host Disease blood
Graft vs Host Disease etiology
Herpes Zoster etiology
Humans
Leukopenia chemically induced
Male
Middle Aged
Multiple Myeloma blood
Multiple Myeloma complications
Prospective Studies
Pyrazines adverse effects
Remission Induction
Thrombocytopenia chemically induced
Transplantation, Homologous
Antineoplastic Agents administration & dosage
Boronic Acids administration & dosage
Multiple Myeloma therapy
Pyrazines administration & dosage
Stem Cell Transplantation
Subjects
Details
- Language :
- English
- ISSN :
- 0301-472X
- Volume :
- 34
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Experimental hematology
- Publication Type :
- Academic Journal
- Accession number :
- 16728282
- Full Text :
- https://doi.org/10.1016/j.exphem.2006.02.020